RadNet’s Wholly-Owned Subsidiary, DeepHealth, and ConcertAI’s TeraRecon Announce Strategic Collaboration Around Integrated AI and Advanced Visualization
RadNet's subsidiary DeepHealth and ConcertAI's TeraRecon announced a strategic collaboration to advance imaging tools and radiology workflow. The partnership will integrate TeraRecon's advanced visualization technology into DeepHealth OS cloud-native Operating System, while incorporating DeepHealth's clinical AI solutions into TeraRecon's AI ecosystem.
The collaboration aims to create a seamless AI-enabled diagnostic experience for radiologists through DeepHealth's Diagnostic Suite™, enhancing diagnostic accuracy and efficiency. As imaging volumes rise, these integrated AI-powered solutions will help radiology departments manage workload while maintaining precision.
Both companies will explore additional areas to integrate AI-driven imaging and workflow automation, potentially including DeepHealth's AI-powered cancer screening capabilities in TeraRecon's ecosystem. The partnership will be showcased at the European Congress of Radiology 2025 in Vienna from February 26 to March 2.
DeepHealth, sussidiaria di RadNet, e TeraRecon di ConcertAI hanno annunciato una collaborazione strategica per migliorare gli strumenti di imaging e il flusso di lavoro in radiologia. La partnership integrerà la tecnologia avanzata di visualizzazione di TeraRecon nel sistema operativo cloud-native DeepHealth OS, incorporando le soluzioni AI cliniche di DeepHealth nell'ecosistema AI di TeraRecon.
La collaborazione mira a creare un'esperienza diagnostica senza soluzione di continuità abilitata dall'AI per i radiologi attraverso il Diagnostic Suite™ di DeepHealth, migliorando l'accuratezza e l'efficienza diagnostica. Con l'aumento dei volumi di imaging, queste soluzioni integrate potenziate dall'AI aiuteranno i reparti di radiologia a gestire il carico di lavoro mantenendo la precisione.
Entrambe le aziende esploreranno ulteriori aree per integrare l'imaging guidato dall'AI e l'automazione del flusso di lavoro, potenzialmente includendo le capacità di screening per il cancro potenziate dall'AI di DeepHealth nell'ecosistema di TeraRecon. La partnership sarà presentata al Congresso Europeo di Radiologia 2025 a Vienna dal 26 febbraio al 2 marzo.
DeepHealth, subsidiaria de RadNet, y TeraRecon de ConcertAI anunciaron una colaboración estratégica para avanzar en las herramientas de imagen y el flujo de trabajo en radiología. La asociación integrará la tecnología avanzada de visualización de TeraRecon en el sistema operativo nativo de la nube DeepHealth OS, mientras incorpora las soluciones de IA clínica de DeepHealth en el ecosistema de IA de TeraRecon.
La colaboración tiene como objetivo crear una experiencia diagnóstica habilitada por IA sin interrupciones para los radiólogos a través del Diagnostic Suite™ de DeepHealth, mejorando la precisión y eficiencia diagnóstica. A medida que aumentan los volúmenes de imagen, estas soluciones integradas impulsadas por IA ayudarán a los departamentos de radiología a gestionar la carga de trabajo manteniendo la precisión.
Ambas empresas explorarán áreas adicionales para integrar la imagen impulsada por IA y la automatización del flujo de trabajo, potencialmente incluyendo las capacidades de detección de cáncer impulsadas por IA de DeepHealth en el ecosistema de TeraRecon. La asociación se presentará en el Congreso Europeo de Radiología 2025 en Viena del 26 de febrero al 2 de marzo.
RadNet의 자회사 DeepHealth와 ConcertAI의 TeraRecon이 이미징 도구 및 방사선학 워크플로우를 발전시키기 위한 전략적 협력을 발표했습니다. 이 파트너십은 TeraRecon의 고급 시각화 기술을 DeepHealth OS 클라우드 네이티브 운영 체제에 통합하고, DeepHealth의 임상 AI 솔루션을 TeraRecon의 AI 생태계에 통합할 것입니다.
협력의 목표는 DeepHealth의 Diagnostic Suite™를 통해 방사선과를 위한 원활한 AI 지원 진단 경험을 창출하여 진단 정확도와 효율성을 향상시키는 것입니다. 이미징 볼륨이 증가함에 따라, 이러한 통합 AI 기반 솔루션은 방사선과 부서가 작업량을 관리하면서 정밀도를 유지하는 데 도움을 줄 것입니다.
양사는 AI 기반 이미징 및 워크플로우 자동화를 통합할 추가 영역을 탐색할 예정이며, 잠재적으로 DeepHealth의 AI 기반 암 스크리닝 기능을 TeraRecon의 생태계에 포함할 수 있습니다. 이 파트너십은 2025년 2월 26일부터 3월 2일까지 비엔나에서 열리는 유럽 방사선학회에서 소개될 것입니다.
DeepHealth, filiale de RadNet, et TeraRecon de ConcertAI ont annoncé une collaboration stratégique pour faire avancer les outils d'imagerie et le flux de travail en radiologie. Le partenariat intégrera la technologie avancée de visualisation de TeraRecon dans le système d'exploitation cloud-native DeepHealth OS, tout en incorporant les solutions d'IA clinique de DeepHealth dans l'écosystème d'IA de TeraRecon.
Cette collaboration vise à créer une expérience diagnostique fluide et assistée par IA pour les radiologues grâce à la Diagnostic Suite™ de DeepHealth, améliorant ainsi la précision et l'efficacité diagnostiques. À mesure que les volumes d'imagerie augmentent, ces solutions intégrées alimentées par l'IA aideront les départements de radiologie à gérer la charge de travail tout en maintenant la précision.
Les deux entreprises exploreront d'autres domaines pour intégrer l'imagerie pilotée par l'IA et l'automatisation des flux de travail, y compris potentiellement les capacités de dépistage du cancer alimentées par l'IA de DeepHealth dans l'écosystème de TeraRecon. Le partenariat sera présenté au Congrès Européen de Radiologie 2025 à Vienne, du 26 février au 2 mars.
Die Tochtergesellschaft von RadNet, DeepHealth, und TeraRecon von ConcertAI haben eine strategische Zusammenarbeit angekündigt, um Bildgebungswerkzeuge und den radiologischen Workflow zu verbessern. Die Partnerschaft wird die fortschrittliche Visualisierungstechnologie von TeraRecon in das cloud-native Betriebssystem DeepHealth OS integrieren und die klinischen KI-Lösungen von DeepHealth in das KI-Ökosystem von TeraRecon einfügen.
Das Ziel der Zusammenarbeit ist es, eine nahtlose, KI-unterstützte diagnostische Erfahrung für Radiologen durch DeepHealths Diagnostic Suite™ zu schaffen, die die diagnostische Genauigkeit und Effizienz erhöht. Angesichts der steigenden Bildgebungsvolumina werden diese integrierten, KI-gestützten Lösungen den Radiologieabteilungen helfen, die Arbeitslast zu bewältigen und gleichzeitig Präzision zu bewahren.
Beide Unternehmen werden zusätzliche Bereiche erkunden, um KI-gesteuerte Bildgebung und Workflow-Automatisierung zu integrieren, möglicherweise einschließlich der KI-gestützten Krebsfrüherkennungsmöglichkeiten von DeepHealth im Ökosystem von TeraRecon. Die Partnerschaft wird auf dem Europäischen Kongress für Radiologie 2025 in Wien vom 26. Februar bis 2. März vorgestellt.
- Strategic integration of TeraRecon's advanced visualization with DeepHealth's cloud platform
- Potential expansion of DeepHealth's AI cancer screening tools to wider market through TeraRecon
- Combined solution addresses growing imaging volume challenges in radiology departments
- Partnership creates unified AI-powered diagnostic workspace enhancing workflow efficiency
- None.
Insights
Strategic AI Integration Positions RadNet for Digital Health Revenue Expansion
This strategic collaboration between RadNet's DeepHealth and ConcertAI's TeraRecon represents a significant advancement in RadNet's digital health strategy, with material implications for its future revenue streams and competitive positioning. The partnership creates a two-way technology integration that enhances both companies' AI capabilities while potentially accelerating market adoption of DeepHealth's solutions.
The integration of TeraRecon's visualization technology into DeepHealth's cloud platform addresses a critical market need as radiology departments face increasing imaging volumes while confronting radiologist shortages. By creating a unified diagnostic workspace, RadNet positions itself to capture additional value from its substantial investment in AI technology, moving beyond its internal network of 350+ imaging centers to reach TeraRecon's extensive customer base.
This collaboration should be viewed within RadNet's broader strategy to diversify revenue beyond traditional imaging services. The company has invested heavily in AI development through DeepHealth, and this partnership provides a commercialization pathway that leverages TeraRecon's established market presence without requiring significant additional sales infrastructure investment from RadNet.
For investors, this represents potential acceleration of RadNet's digital health revenue stream, which carries higher margins than traditional imaging services. While the financial impact may not be immediate, the partnership establishes a foundation for recurring SaaS revenue that could meaningfully contribute to RadNet's top-line growth in 2025-2026.
The medical imaging AI market is projected to grow at a CAGR of 26% through 2030, reaching approximately $8 billion. RadNet's strategic positioning through this partnership allows it to participate in this high-growth segment while simultaneously improving operational efficiency within its core imaging center business.
Notably, the collaboration's focus on cancer screening capabilities aligns with value-based care initiatives and could strengthen RadNet's position as these screening programs become increasingly reimbursed by payers seeking to improve early detection rates and reduce downstream treatment costs.
While the press release doesn't disclose financial terms, this type of integration typically involves revenue-sharing arrangements that could provide RadNet with a scalable growth vector beyond its traditional geographic expansion model. This represents a potential inflection point in the company's evolution from a pure imaging center operator to a technology-enabled healthcare services provider with diversified revenue streams.
- DeepHealth’s cloud-native Diagnostic Suite™ will integrate TeraRecon’s SaaS-based advanced visualization capabilities, creating a unified AI-powered diagnostic workspace that enhances workflows and expands access to advanced diagnostic tools across diverse healthcare settings.
- The collaboration will also integrate DeepHealth’s clinical AI solutions into TeraRecon’s AI ecosystem, augmenting its capabilities and expanding its impact in diagnostic imaging.
- Both companies will continue to explore new opportunities to leverage each other’s AI solutions and distribute AI-driven imaging and workflow automation.
LOS ANGELES and SOMERVILLE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT) and ConcertAI’s TeraRecon, a leader in medical imaging advanced visualization, clinical AI, and workflow automation, announced today a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow. This collaboration is first designed to create a seamless AI-enabled diagnostic experience for radiologists and imaging specialists through integrating TeraRecon’s advanced visualization (AV) technology into DeepHealth OS cloud-native Operating System. Additionally, the collaboration seeks to incorporate DeepHealth’s clinical AI solutions into TeraRecon’s AI ecosystem, enabling physicians to deliver precise and timely diagnostic interpretations.
“ConcertAI will be aligning its TeraRecon Advanced Visualization and Clinical AI solutions with DeepHealth’s AI-enabled operating system to deliver optimized operational and interpretive workflows to radiologists,” said Jeff Elton, PhD, CEO of ConcertAI. “This two-way collaboration, integrating DeepHealth’s clinical AI technology into the TeraRecon AI ecosystem, can provide more radiologists with essential tools to enhance diagnostic efficiency, enabling better patient care.”
As imaging volumes continue to rise, radiology departments face increasing pressure to manage workload efficiently while maintaining diagnostic accuracy. AI-powered solutions have demonstrated their potential in streamlining workflows and improving precision, making integrated technologies essential for the future of medical imaging.
DeepHealth OS is a secure, scalable, cloud-native platform that personalizes AI-powered workspaces for radiology teams, enabling greater collaboration and efficiency. DeepHealth’s Diagnostic Suite™, which harnesses the cloud-native capabilities of DeepHealth OS delivers seamless workflow integration to meet the evolving demands of radiologists through interoperable, reliable, highly scalable unified diagnostic workspace.
The integration of TeraRecon’s advanced visualization capabilities with DeepHealth’s OS and Diagnostic Suite will enhance diagnostic accuracy and efficiency and streamline radiologists’ workflows by enabling radiologists to make faster, more informed decisions with greater ease.
“At DeepHealth, we are committed to leveraging advanced AI to enhance radiology workflows, elevate the experience of care teams, and improve patient care,” said Kees Wesdorp, PhD, President and CEO of RadNet’s Digital Health division. “Partnering with TeraRecon allows us to integrate industry-leading visualization and clinical AI technology, equipping radiologists with the tools to improve efficiency and reduce variability. This collaboration strengthens DeepHealth OS, driving innovation in medical imaging.”
Additionally, the two companies are exploring the integration of several of DeepHealth’s AI-powered cancer screening capabilities into TeraRecon’s AI ecosystem, further strengthening TeraRecon's AI-powered imaging solutions and making these essential screening tools more widely available. These enhancements would contribute to TeraRecon’s comprehensive cloud-based imaging suite, which spans from diagnosis to research, offering end-to-end advanced imaging solutions for a broader range of healthcare providers.
This collaboration marks the beginning of a broader engagement between TeraRecon and DeepHealth, as both companies explore additional areas to integrate AI-driven imaging and workflow automation. By continuing to expand their joint capabilities, they aim to provide radiologists with seamless diagnostic tools that enhance precision, efficiency, and better care delivery.
For more information, visit the TeraRecon (#AI-13) and DeepHealth (#507, X5) booths at the European Congress of Radiology 2025, which will be held between 26 February and 2 March in Vienna, Austria.
About ConcertAI
ConcertAI is the leader in predictive and generative AI SaaS and multi-modal data solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com and www.terarecon.com.
About DeepHealth
DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth’s portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, ConcertAI, TeraRecon, and DeepHealth’s informatics, hardware and software product portfolios and the collaboration’s impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.
For media inquiries, reach out to:
ConcertAI
Treble
McKenzie Covell
concertai@treblepr.com
DeepHealth
Andra Axente
Communications Director
Phone: +31 614 440971
Email: andra.axente@deephealth.com
FAQ
What is the strategic collaboration between DeepHealth and TeraRecon about?
How will RDNT's DeepHealth and TeraRecon collaboration benefit radiologists?
What AI capabilities will be shared between RDNT's DeepHealth and TeraRecon?
When and where will RDNT's DeepHealth and TeraRecon showcase their collaboration?
What challenges in radiology does the RDNT subsidiary's partnership with TeraRecon address?
